Longboard begins world Section 3 trial for Dravet syndrome drug By Investing.com
LA JOLLA, Calif. - Longboard Prescription drugs, Inc. (NASDAQ:LBPH) has launched a…
Longboard Prescription drugs Broadcasts Optimistic Interim Evaluation Outcomes from the Open-Label Extension (OLE) of the Part 1b/2a PACIFIC Examine Evaluating Bexicaserin in Members with Developmental and By Investing.com
Bexicaserin achieved an general median seizure discount of 57.7% in countable motor…
Baird retains Outperform on Longboard shares forward of upcoming investor occasion By Investing.com
On Friday, Baird reaffirmed its Outperform ranking on shares of Longboard Prescription…
